-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: IP
Innovative China: Policies for the Future
As the second largest and fastest growing market for biotechnology products, China needs no introduction. The opportunity to heal, fuel, and feed 1.3 billion global citizens stands in clear contrast with the regulatory, financial, and political frameworks that present challenges to the life science industry’s external access to the evolving Chinese market. On Tuesday at the 2011 BIO International Convention, a panel discussion titled “Innovative China: Policies for the Future” addressed the future of the Read More >
Blogging from #BIO2011
by Stephen Albainy-Jenei, from Patent Baristas You can keep up with what’s happening at BIO 2011 on BIOTechNOW (@BIOTechNOW) plus all the BIO Official Bloggers hitting the floor at the convention. I’ll be in attendance as well as participating in the BIO Official Blogger network throughout the week. If you’d like to meet up during the conference, drop me a note and we’ll schedule some time to have coffee together.
Docs at BIO: Patent Litigation Tactics and Strategies for Biosimilars
One of the highlights of the afternoon sessions at the BIO International Convention was a seminar appropriately entitled “A Brave New World: Patent Litigation Tactics and Strategies for Biosimilars,” where an experienced panel of patent attorneys presented their interpretation of the new biosimilars pathway of the Biologics Price Competition and Innovation Act and speculated on some of the potential issues that will arise once the statute is put into practice. From Patent Docs.
Intellectual Property problems for personalized medicine
Amid growing interest in personalized medicine that stands to provide patients with better care at reduced costs, legal battles over gene patents ensue, threatening the viability of widespread implementation. On this topic authors Jennifer Gordon, Steve Lendaris and Anna Volftsun (layers at Baker Botts LLP) wrote a very interesting opinion article for The Scientist on the topic. They also examine the barriers to personalized medicine, including a pending decision in the Myriad Genetics case, and Read More >
BIO’s IP Priorities for 2011
As we start a new year, the BIO Intellectual Property Department has determined their 2011 priorities. Intellectual Property remains a foundational priority for BIO and our 1100 biotechnology company members. BIO’s IP department has approved the following priorities for 2011: 1) PTO reforms to improve efficient, timely and quality examination 2) Congressional patent reform legislation 3) Improving IP protection in key foreign markets 4) IP legal developments in the courts 5) Protecting the breadth and flexibility of the patent Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bayh-Dole, BIO, Biotechnology Industry Organization, economic development, Intellectual Property, International, IP, Patent Reform, patent reform in foreign markets, patents, Supreme Court, Technology Transfer, Technology Transfer, United States Patent and Trademark Office
Tags: Bayh-Dole, BIO, Biotechnology Industry Organization, economic development, Intellectual Property, International, IP, Patent Reform, patent reform in foreign markets, patents, Supreme Court, Technology Transfer, Technology Transfer, United States Patent and Trademark Office
